ugichem GmbH, an Innsbruck, Austria-based developer of a novel antisense drug platform, raised €2.25m in funding.
The Backers included Austria’s Research Promotion Agency FFG, which provided a grant of €850k and existing investors, which provided an equity financing of €1.4m.
The company intends to use the funds to advance preclinical Ugimer drug development for immune-mediated inflammatory diseases (IMID).
Led by Dr Holger Bock, CEO, ugichem leverages its proprietary platform to develop a pipeline of antisense drugs addressing unmet medical needs in indications involving inflammatory processes with a current focus on rheumatoid arthritis.
FinSMEs
28/05/2013